Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03301038 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

Study acronym: RICHH
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Children's Hospital of Philadelphia to Children's Hospital of Philadelphia Show 5 more changesShow less
    • Primary completion date: Dec 2027 to Dec 1, 2027
    • Study completion date: Dec 2030 to Dec 1, 2030
    • Eligibility criteria expanded, about 11 words
    • Site details revised
    • Publications: details revised at 3 of 3 entries
  2. Primary completion date: Dec 2026 to Dec 2027v16
  3. Study Status, Eligibilityv15
  4. Enrollment target: 30 to 60
    • Study description revised
    v14
  5. Enrollment target: 18 to 30
    • Primary completion date: Dec 2023 to Dec 2026
    • Study description revised
    v13
Show 11 earlier versionsHide 11 earlier versions
  1. Start date: Jun 19, 2018 to Jul 25, 2018v12
  2. Secondary endpoints: details revised at 1 of 3 entries
    • Study description expanded, about 4 words
    v11
  3. Eligibility criteria expanded, about 41 wordsv10
  4. Site contact updatedv9
  5. Re-verified, no change to tracked fieldsv8
  6. Eligibility criteria revisedv7
  7. Re-verified, no change to tracked fieldsv6
  8. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2018 to Jun 19, 2018
    • Site details revised
    v5
  9. Start date: May 1, 2018 to Jun 2018
    • Study site revised
    v4
  10. Start date: Dec 2018 to May 1, 2018v3
  11. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and/or hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.
Trial Details
NCT Number NCT03301038
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions
(from sponsor)		 Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria
Related terms Genetic Diseases, Inborn, Hypercalcemia, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuria, Hypercalciuric Hypercalcemia, Nephrocalcinosis
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov